News coverage about Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has trended somewhat positive on Tuesday, Accern reports. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nymox Pharmaceutical Corporation earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 47.0734371600942 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Separately, ValuEngine lowered Nymox Pharmaceutical Corporation from a “hold” rating to a “sell” rating in a report on Monday, July 24th.
Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) traded down 1.66% on Tuesday, hitting $3.56. The stock had a trading volume of 117,071 shares. The stock’s 50-day moving average price is $3.86 and its 200 day moving average price is $3.92. The company’s market cap is $186.43 million. Nymox Pharmaceutical Corporation has a 52 week low of $2.67 and a 52 week high of $5.10.
In other Nymox Pharmaceutical Corporation news, Director James George Robinson bought 10,000 shares of Nymox Pharmaceutical Corporation stock in a transaction dated Thursday, August 3rd. The stock was bought at an average cost of $3.73 per share, for a total transaction of $37,300.00. Following the purchase, the director now owns 3,077,550 shares of the company’s stock, valued at approximately $11,479,261.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 54.00% of the company’s stock.
WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Nymox Pharmaceutical Corporation (NYMX) Share Price” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.com-unik.info/2017/10/31/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-nymox-pharmaceutical-corporation-nymx-share-price.html.
Nymox Pharmaceutical Corporation Company Profile
Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.
What are top analysts saying about Nymox Pharmaceutical Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nymox Pharmaceutical Corporation and related companies.